

0300 #3  
Box 599


|  |                             |                             |
|--|-----------------------------|-----------------------------|
| <p style="text-align: center;"><b>IN THE<br/>UNITED STATES<br/>PATENT AND TRADEMARK<br/>OFFICE</b></p> <p style="text-align: center;">OCT 11 2001</p> <p style="text-align: center;">O I P E J C I S G<br/>PATENT &amp; TRADEMARK OFFICE</p> | <i>Application Number</i>   | 09/910,059                  |
|  | <i>Filing Date</i>          | July 23, 2001               |
|  | <i>First Named Inventor</i> | Clive Graham Copley, et al. |
|  | <i>Group Art Unit</i>       | 1642                        |
|  | <i>Examiner Name</i>        | To be assigned              |
|  | <i>Attorney Docket No.</i>  | 1991-209                    |
| <p><i>Title of the invention:</i> <b>MONOCLONAL ANTIBODY TO CEA, CONJUGATES COMPRISING SAID ANTIBODY, AND THEIR THERAPEUTIC USE IN AN ADEPT SYSTEM</b></p>   |                             |                             |

### RESPONSE TO NOTICE TO COMPLY

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In response to the Notice to Comply mailed August 21, 2001, Applicants submit herewith, as requested in the Notice, a paper copy of the substitute Sequence Listing of the instant application and a diskette containing the substitute Sequence Listing of the Application. Applicants hereby state that the sequence information contained in the paper and computer copies of this sequence is identical and that the Sequence Listing contains no new matter.

|                                |   |           |              |          |                  |
|--------------------------------|---|-----------|--------------|----------|------------------|
| <b>RESPECTFULLY SUBMITTED,</b> |   |           |              |          |                  |
| NAME AND REG. NUMBER           | Martha Cassidy, Reg. No. 44,066   |           |              |          |                  |
| SIGNATURE                      |  |           |              | DATE     | October 11, 2001 |
| Address                        | ROTHWELL, FIGG, ERNST & MANBECK, pc<br>Suite 701-East, 555 13th Street, N.W.        |           |              |          |                  |
| City                           | Washington  | State     | D.C.         | Zip Code | 20004            |
| Country                        | U.S.A.  | Telephone | 202-783-6040 | Fax      | 202-783-6031     |



UNITED STATES PATENT AND TRADEMARK OFFICE

Copy

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

| APPLICATION NUMBER | FILING/RECEIPT DATE | FIRST NAMED APPLICANT | ATTORNEY DOCKET NUMBER |
|--------------------|---------------------|-----------------------|------------------------|
| 09/910,059         | 07/23/2001          | Clive Graham Copley   | 1991-209               |

CONFIRMATION NO. 4833

6449

ROTHWELL, FIGG, ERNST & MANBECK, P.C.  
555 13TH STREET, N.W.  
SUITE 701, EAST TOWER  
WASHINGTON, DC 20004

## FORMALITIES LETTER



\*OC000000006453705\*

Date Mailed: 08/21/2001

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*

Ahmad

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY